Next Article in Journal
The Biochemical Toxin Arsenal from Ant Venoms
Next Article in Special Issue
Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane Insertion and Pore Formation
Previous Article in Journal
Preventive Effects of Bee Venom Derived Phospholipase A2 on Oxaliplatin-Induced Neuropathic Pain in Mice
Previous Article in Special Issue
Anthrax Susceptibility: Human Genetic Polymorphisms Modulating ANTXR2 Expression
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Toxins 2016, 8(1), 28; doi:10.3390/toxins8010028

Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor

1
Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
2
Center for Disease Control and Prevention of Navy, Beijing 101113, China
*
Authors to whom correspondence should be addressed.
Academic Editor: Shihui Liu
Received: 30 October 2015 / Revised: 25 December 2015 / Accepted: 13 January 2016 / Published: 20 January 2016
(This article belongs to the Collection Anthrax Toxins)
View Full-Text   |   Download PDF [2375 KB, uploaded 20 January 2016]   |  

Abstract

Anthrax toxin is the major virulence factor produced by Bacillus anthracis. Protective antigen (PA) is the key component of the toxin and has been confirmed as the main target for the development of toxin inhibitors. The inhibition of the binding of PA to its receptor, capillary morphogenesis protein-2 (CMG2), can effectively block anthrax intoxication. The recombinant, soluble von Willebrand factor type A (vWA) domain of CMG2 (sCMG2) has demonstrated potency against anthrax toxin. However, the short half-life of sCMG2 in vivo is a disadvantage for its development as a new anthrax drug. In the present study, we report that HSA-CMG2, a protein combining human serum albumin (HSA) and sCMG2, produced in the Pichia pastoris expression system prolonged the half-life of sCMG2 while maintaining PA binding ability. The IC50 of HSA-CMG2 is similar to those of sCMG2 and CMG2-Fc in in vitro toxin neutralization assays, and HSA-CMG2 completely protects rats from lethal doses of anthrax toxin challenge; these same challenge doses exceed sCMG2 at a sub-equivalent dose ratio and overwhelm CMG2-Fc. Our results suggest that HSA-CMG2 is a promising inhibitor of anthrax toxin and may contribute to the development of novel anthrax drugs. View Full-Text
Keywords: Bacillus anthracis; protective antigen; anthrax toxin inhibitor; CMG2; HSA Bacillus anthracis; protective antigen; anthrax toxin inhibitor; CMG2; HSA
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Li, L.; Guo, Q.; Liu, J.; Zhang, J.; Yin, Y.; Dong, D.; Fu, L.; Xu, J.; Chen, W. Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor. Toxins 2016, 8, 28.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top